Wikipedia

Triosephosphate isomerase deficiency

(redirected from Triose Phosphate Isomerase deficiency)
Triosephosphate isomerase deficiency
Other namesTriose phosphate-isomerase deficiency [1]
Autosomal recessive - en.svg
Triosephosphate isomerase deficiency has an autosomal recessive pattern of inheritance.
SpecialtyHematology Edit this on Wikidata

Triosephosphate isomerase deficiency is a rare autosomal recessive[2] metabolic disorder which was initially described in 1965.[3]

It is a unique glycolytic enzymopathy that is characterized by chronic haemolytic anaemia, cardiomyopathy, susceptibility to infections, severe neurological dysfunction, and, in most cases, death in early childhood.[4] The disease is exceptionally rare with fewer than 100 patients diagnosed worldwide.

Genetics

Thirteen different mutations in the respective gene, which is located at chromosome 12p13 and encodes the ubiquitous housekeeping enzyme triosephosphate isomerase (TPI), have been discovered so far.[4] TPI is a crucial enzyme of glycolysis and catalyzes the interconversion of dihydroxyacetone phosphate and glyceraldehyde-3-phosphate. A marked decrease in TPI activity and an accumulation of dihydroxyacetone phosphate have been detected in erythrocyte extracts of homozygous (two identical mutant alleles) and compound heterozygous (two different mutant alleles) TPI deficiency patients. Heterozygous individuals are clinically unaffected, even if their residual TPI activity is reduced. Recent work suggests that not a direct inactivation, but an alteration in TPI dimerization might underlie the pathology.[2] This might explain why the disease is rare, but inactive TPI alleles have been detected at higher frequency implicating a heterozygote advantage of inactive TPI alleles.

The most common mutation causing TPI deficiency is TPI Glu104Asp. All carriers of the mutation are descendants of a common ancestor, a person that lived in what is today France or England more than 1000 years ago.[5]

See also

  • List of hematologic conditions

References

  1. ^ "Triosephosphate isomerase deficiency | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 11 April 2019.
  2. ^ a b Ralser, Markus; Gino Heeren; Michael Breitenbach; Hans Lehrach; Sylvia Krobitsch (December 20, 2006). Janbon, Guilhem (ed.). "Triose Phosphate Isomerase Deficiency Is Caused by Altered Dimerization–Not Catalytic Inactivity–of the Mutant Enzymes". PLOS ONE. 1 (1): e30. Bibcode:2006PLoSO...1...30R. doi:10.1371/journal.pone.0000030. PMC 1762313. PMID 17183658.
  3. ^ Schneider, Arthur S.; William N. Valentine; Hattori M; H. L. Heins Jr (1965). "Hereditary Hemolytic Anemia with Triosephosphate Isomerase Deficiency". New England Journal of Medicine. 272 (5): 229–235. doi:10.1056/NEJM196502042720503. PMID 14242501.
  4. ^ a b Schneider, Arthur S. (Mar 2000). "Triosephosphate isomerase deficiency: historical perspectives and molecular aspects". Best Practice & Research Clinical Haematology. 13 (1): 119–140. doi:10.1053/beha.2000.0061. PMID 10916682.
  5. ^ Schneider A, Westwood B, Yim C, et al. (1996). "The 1591C mutation in triosephosphate isomerase (TPI) deficiency. Tightly linked polymorphisms and a common haplotype in all known families". Blood Cells Mol. Dis. 22 (2): 115–25. doi:10.1006/bcmd.1996.0019. PMID 8931952.

External links

Classification
External resources
This article is copied from an article on Wikipedia® - the free encyclopedia created and edited by its online user community. The text was not checked or edited by anyone on our staff. Although the vast majority of Wikipedia® encyclopedia articles provide accurate and timely information, please do not assume the accuracy of any particular article. This article is distributed under the terms of GNU Free Documentation License.

Copyright © 2003-2025 Farlex, Inc Disclaimer
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.